PMID- 33402601
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220603
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 59
IP  - 1
DP  - 2022 Jan-Mar
TI  - Different administration methods of endostar combined with second-line 
      chemotherapy in advanced malignancies.
PG  - 26-32
LID - 10.4103/ijc.IJC_537_19 [doi]
AB  - BACKGROUND: This study aimed to compare the therapeutic efficacy and the side 
      effects of different endostar administration methods in patients with advanced 
      malignancy who underwent second-line chemotherapy. METHODS: 98 patients with 
      advanced malignancies were divided into 2 groups based on the delivery methods of 
      endostar, including drip intravenous administration of endostar (DE) group and 
      continuous intravenous administration of endostar (CE) group. Response rate (RR), 
      disease control rate (DCR), and quality of life (QOL) of the patients were 
      examined to evaluate the therapeutic efficacy, and toxicity reactions were 
      analyzed to evaluate the adverse effects. RESULTS: Compared with the DE group, 
      the therapeutic efficacy of CE has been slightly improved, but the difference did 
      not reach statistical significance (P > 0.05). Additionally, no different 
      incidence rate was observed in toxic reactions, including leukopenia, 
      thrombocytopenia, nausea and vomiting, diarrhea, and hepatic function damage, 
      between the DE and CE groups (P > 0.05). CONCLUSION: In conclusion, no 
      significant difference was observed between the traditional intravenous drip of 
      endostar group and the intravenous drip followed by continuous pumping of 
      endostar group in the patients with advanced malignancies.
FAU - Chen, Shaoping
AU  - Chen S
AD  - Department of Oncology, Dongying People's Hospital, Shandong, China.
FAU - Yang, Jianmei
AU  - Yang J
AD  - Department of Oncology, Dongying People's Hospital, Shandong, China.
FAU - Gao, Xin
AU  - Gao X
AD  - Department of Oncology, Dongying People's Hospital, Shandong, China.
FAU - Liu, Qiang
AU  - Liu Q
AD  - Department of Oncology, Dongying People's Hospital, Shandong, China.
FAU - Wang, Xunguo
AU  - Wang X
AD  - Department of Oncology, Dongying People's Hospital, Shandong, China.
FAU - Guo, Yanchun
AU  - Guo Y
AD  - Department of Oncology, Dongying People's Hospital, Shandong, China.
FAU - Liu, Ruibao
AU  - Liu R
AD  - Department of Oncology, Dongying People's Hospital, Shandong, China.
FAU - Wang, Fang
AU  - Wang F
AD  - Department of Oncology, Dongying People's Hospital, Shandong, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
RN  - 0 (Endostatins)
RN  - 0 (Recombinant Proteins)
RN  - GVG18ZDN65 (endostar protein)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Endostatins/adverse effects
MH  - Humans
MH  - *Lung Neoplasms/pathology
MH  - Neoplasm Staging
MH  - *Quality of Life
MH  - Recombinant Proteins
OTO - NOTNLM
OT  - Endostar
OT  - malignancy
OT  - quality of life
OT  - second-line chemotherapy
COIS- None
EDAT- 2021/01/07 06:00
MHDA- 2022/06/07 06:00
CRDT- 2021/01/06 05:39
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
PHST- 2021/01/06 05:39 [entrez]
AID - 302940 [pii]
AID - 10.4103/ijc.IJC_537_19 [doi]
PST - ppublish
SO  - Indian J Cancer. 2022 Jan-Mar;59(1):26-32. doi: 10.4103/ijc.IJC_537_19.